Mergers & Acquisitions - Biotechnology, Gilead Sciences

Filter

Popular Filters

Gilead expands hepatitis C R&D portfolio with $11 billion buy of Pharmasset

22-11-2011

In its biggest M&D deal to date, Gilead Sciences (Nasdaq: GILD) says it has signed a definitive agreement…

Anti-viralsBiotechnologyGilead SciencesMergers & AcquisitionsmericitabinePharmaceuticalPharmasset

Company Spotlight

ImmunoGen

ImmunoGen

Back to top